At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Isavuconazonium sulfate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects
In Brief
A Phase 2 clinical trial evaluating Isavuconazonium sulfate for Invasive Mucormycosis and Invasive Aspergillosis. Completed, enrolled 31 participants across 10 sites in 3 countries.
Detailed Summary
The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Mucormycosis, Invasive Aspergillosis
CountriesBelgium, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartAug 2019
Primary CompletionDec 2022
TodayJul 2026
First PostedJan 25, 2019
Enrollment StartAug 22, 2019
Primary CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.4 years ago
Interventions
Isavuconazonium sulfatedrug
Intravenous (IV) infusion
Isavuconazonium sulfatedrug
Oral capsule